AKT1 and ovarian carcinoma: In our previous studies, we showed that MK-2206 could enhance the efficacy of cisplatin and paclitaxel in both Akt-active SKOV3 and Akt-inactive ES2 ovarian cancer cells (Lin et al., 2015).